Pilot Trial of Enasidenib (AG-221) Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients With IDH2 Mutation
Phase of Trial: Phase I
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs Enasidenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 29 Jul 2019 Status changed from not yet recruiting to recruiting.
- 08 Jul 2019 Planned initiation date changed from 15 Jun 2019 to 15 Oct 2019.
- 25 Jan 2019 Planned initiation date changed from 15 Dec 2018 to 15 Jun 2019.